ARCHIVES

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

American cancer Society Funds 84 Research Grants. NCI, NIGMS To Support Synchrotron Beamlines.

November 16, 2001

In Brief: Frederickson Resigns As NIH Director, Says He Wants “One More Career: As Scientist, Physician

June 25, 1981

Novel Agents Promise Relief From Hematologic Side Effects

July 27, 2001

Interferon “Hysteria” Prompts ASCO To Warn Against Expecting Immediate Benefits

June 20, 1980

RFPs Available, Contract Awards, Sole Source Negotiations

June 25, 1976

Duke Picks Lyerly To Direct Cancer Center

May 2, 2003